[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Scholar Rock Holding Corp (SRRK)

Scholar Rock Holding Corp (SRRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,590,540
  • Shares Outstanding, K 119,828
  • Annual Sales, $ 0 K
  • Annual Income, $ -377,940 K
  • EBIT $ -410 M
  • EBITDA $ -411 M
  • 60-Month Beta 0.69
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 23.76

Options Overview Details

View History
  • Implied Volatility 57.74% (-3.84%)
  • Historical Volatility 44.13%
  • IV Percentile 20%
  • IV Rank 9.09%
  • IV High 152.07% on 09/22/25
  • IV Low 48.31% on 07/21/25
  • Expected Move (DTE 15) 2.13 (4.02%)
  • Put/Call Vol Ratio 0.89
  • Today's Volume 89
  • Volume Avg (30-Day) 178
  • Put/Call OI Ratio 0.94
  • Today's Open Interest 9,881
  • Open Int (30-Day) 11,318
  • Expected Range 50.72 to 54.97

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.84
  • Number of Estimates 6
  • High Estimate $-0.79
  • Low Estimate $-0.89
  • Prior Year $-0.98
  • Growth Rate Est. (year over year) +14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
43.23 +22.23%
on 06/11/26
56.54 -6.54%
on 06/29/26
+5.45 (+11.50%)
since 06/01/26
3-Month
43.23 +22.23%
on 06/11/26
56.54 -6.54%
on 06/29/26
+3.49 (+7.07%)
since 04/01/26
52-Week
27.07 +95.20%
on 11/07/25
56.54 -6.54%
on 06/29/26
+19.08 (+56.52%)
since 07/01/25

Most Recent Stories

More News
Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating...

SRRK : 52.84 (-3.93%)
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 134,345 shares of its common stock to eleven newly hired employees,...

SRRK : 52.84 (-3.93%)
Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating...

SRRK : 52.84 (-3.93%)
Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating...

SRRK : 52.84 (-3.93%)
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 38,481 shares of its common stock to six newly hired employees,...

SRRK : 52.84 (-3.93%)
Scholar Rock Q1 Earnings Call Highlights

Scholar Rock (NASDAQ:SRRK) said the U.S. Food and Drug Administration has accepted for review its resubmitted Biologics License Application for apitegromab, the company’s investigational treatment for...

SRRK : 52.84 (-3.93%)
Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights

FDA accepted apitegromab Biologics License Application (BLA) for treatment of children and adults with spinal muscular atrophy (SMA) with September 30, 2026 Prescription Drug User Fee Act (PDUFA) action...

SRRK : 52.84 (-3.93%)
Scholar Rock Braces for Approval Clarity but Commercial Questions Linger

Barchart Research What to Expect from SRRK Earnings SRRK Generated May 6, 2026 Current Price $47.11 EPS Estimate $$-0.82 Consensus Rating Strong Buy Average Move 5.88% Scholar Rock Braces for Approval...

SRRK : 52.84 (-3.93%)
Scholar Rock to Present at the BofA Securities 2026 Health Care Conference

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating...

SRRK : 52.84 (-3.93%)
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 89,304 shares of its common stock to nine newly hired employees,...

SRRK : 52.84 (-3.93%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

Scholar Rock Holding Corporation is a biopharmaceutical company. It focused on the discovery and development of medicines for treatment of serious diseases. The company's product candidate includes SRK-015 and BMP6 which is in pre-clinical stage. Scholar Rock Holding Corporation is based in Cambridge,...

See More

Key Turning Points

3rd Resistance Point 56.47
2nd Resistance Point 55.75
1st Resistance Point 54.29
Last Price 52.84
1st Support Level 52.11
2nd Support Level 51.39
3rd Support Level 49.93

See More

52-Week High 56.54
Last Price 52.84
Fibonacci 61.8% 45.28
Fibonacci 50% 41.81
Fibonacci 38.2% 38.33
52-Week Low 27.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.